A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants
- Conditions
- Healthy Study Participants
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 64
- Registration Number
- NCT06312566
- Locations
- 🇯🇵
EP0231 1, Sumida-ku, Japan
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 12
- Registration Number
- NCT06149559
- Locations
- 🇮🇹
Mg0006 40733, Napoli, Italy
🇺🇸Mg0006 50574, Denton, Texas, United States
🇮🇹Mg0006 40290, Bologna, Italy
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 8
- Registration Number
- NCT06055959
- Locations
- 🇬🇧
Mg0014 40736, London, United Kingdom
🇺🇸Mg0014 50168, Chicago, Illinois, United States
🇺🇸Mg0014 50574, Denton, Texas, United States
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 207
- Registration Number
- NCT06055985
- Locations
- 🇺🇸
Pd0060 50506, Phoenix, Arizona, United States
🇺🇸Pd0060 50590, Scottsdale, Arizona, United States
🇺🇸Pd0060 50608, Little Rock, Arkansas, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Chronic Plaque PsoriasisModerate to Severe Chronic Plaque Psoriasis
- Interventions
- Other: Placebo
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 133
- Registration Number
- NCT06011733
- Locations
- 🇨🇳
Ps0041 20023, Beijing, China
🇨🇳Ps0041 20247, Beijing, China
🇨🇳Ps0041 20306, Beijing, China
A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
- Conditions
- Healthy Study Participants
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 73
- Registration Number
- NCT05845645
- Locations
- 🇺🇸
Up0073 10001, Glendale, California, United States
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 62
- Registration Number
- NCT05681715
- Locations
- 🇺🇸
Mg0020 50092, Orange, California, United States
🇺🇸Mg0020 50099, San Francisco, California, United States
🇺🇸Mg0020 50561, Lexington, Kentucky, United States
A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 63
- Registration Number
- NCT05643794
- Locations
- 🇬🇧
Fm0001 4405, Blackpool, United Kingdom
🇬🇧Fm0001 4406, Cannock, United Kingdom
🇬🇧Fm0001 4407, Leeds, United Kingdom
A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 21
- Registration Number
- NCT05626439
- Locations
- 🇺🇸
Up0104 1001, Baltimore, Maryland, United States
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Minzasolmin (UCB0599)
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 374
- Registration Number
- NCT05543252
- Locations
- 🇺🇸
Pd0055 50506, Phoenix, Arizona, United States
🇺🇸Pd0055 50519, Fountain Valley, California, United States
🇺🇸Pd0055 50385, Fresno, California, United States